Render Target: SSR
Render Timestamp: 2024-11-24T13:18:34.476Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-20 06:17:21.359
Product last modified at: 2024-09-20T07:05:33.800Z
1% for the planet logo
PDP - Template Name: Growth Factors and Cytokines
PDP - Template ID: *******9ad1159

Mouse Transforming Growth Factor β1 (mTGF-β1) #5231

Inquiry Info. # 5231

Please see our recommended alternatives.

    Product Information

    Product Usage Information

    Reconstitution:

    With carrier: Add sterile 20 mM citrate, pH 3.0 to a final mTGF-β1 concentration of greater than 50 μg/ml. Solubilize for 30 minutes at room temperature with occasional gentle vortexing.

    Carrier free: Add sterile 20 mM citrate, pH 3.0, or 20 mM citrate, pH 3.0 containing protein to minimize absorption of mTGF-β1 to surfaces. Solubilize for 30 minutes at room temperature with occasional gentle vortexing. Stock mTGF-β1 should be greater than 50 μg/ml.

    Formulation

    With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg mTGF-β1. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.

    Storage

    Stable in lyophilized state at -20°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.
    Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

    Product Description

    MW (kDa) 13
    Purity >98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mTGF-β1. All lots are greater than 98% pure.
    Endotoxin Less than 0.01 ng endotoxin/1 μg mTGF-β1.
    Activity The bioactivity of recombinant mTGF-β1 was determined by assessing inhibition of IL-4 induced HT-2 cell proliferation. The ED50 of each lot is between 40-200 pg/ml.
    Molecular Formula Recombinant mTGF-β1 contains no "tags" and the nonglycosylated protein has a calculated MW of 12,810. DTT-reduced protein migrates as a 13 kDa polypeptide and the non-reduced cystine-linked homodimer migrates as a 25 kDa protein. The expected amino-terminal ALDTN of recombinant mTGF-β1 was verified by amino acid sequencing.

    Source / Purification

    Recombinant mouse TGF-β1 (hTGF-β1) Ala279-Ser390 (Accession #NP_035707) was expressed in human 293 cells at Cell Signaling Technology.

    Background

    TGF-β1 activities include proliferation, angiogenesis, and promotion or inhibition of many immune events (1-3). TGF-β1 is produced by a number of cell types including regulatory T cells, fibroblasts, epithelial cells, and endothelial cells (3). TGF-β1 binds to TβRII homodimer, which then complexes with TβRI homodimer (1,4). The oligomeric receptor complex phosphorylates subsets of the Smad proteins that then act to induce and repress a number of target genes (1,3,4). TGF-β1 binding can also activate the Erk2, p38, and JNK pathways via TAK1 (4). TGF-β1 appears to promote late stage progression and metastasis in some cancers (1,2).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.